Diversify Wealth Management LLC Buys 54,488 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Diversify Wealth Management LLC lifted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 734.3% during the first quarter, HoldingsChannel.com reports. The firm owned 61,908 shares of the company’s stock after purchasing an additional 54,488 shares during the quarter. Diversify Wealth Management LLC’s holdings in Teva Pharmaceutical Industries were worth $1,865,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Legal & General Group Plc boosted its holdings in Teva Pharmaceutical Industries by 6.8% in the 4th quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after purchasing an additional 228,189 shares during the period. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth $1,098,060,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 8.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock worth $33,506,000 after purchasing an additional 80,106 shares during the period. Hudson Bay Capital Management LP raised its position in shares of Teva Pharmaceutical Industries by 87.5% in the third quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company’s stock worth $4,545,000 after buying an additional 105,000 shares in the last quarter. Finally, TD Asset Management Inc raised its position in shares of Teva Pharmaceutical Industries by 47.1% in the fourth quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock worth $11,517,000 after buying an additional 118,075 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $31.80 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $36.56 billion, a P/E ratio of 23.91, a PEG ratio of 3.42 and a beta of 0.86. The stock has a 50-day moving average price of $34.00 and a 200-day moving average price of $32.70. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The company had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Richard Daniell sold 30,000 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the transaction, the executive vice president directly owned 172,184 shares in the company, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 465,931 shares of company stock valued at $16,332,989. Insiders own 0.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. UBS Group boosted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Barclays lifted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.